DrugBank

MAY 22, 2024

In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Beyond Proteins: DNA and RNA Frontier The story doesn’t end with proteins.

Small Molecule 96

Small Molecule RNA DNA Pharmaceutical Companies 96

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. About Eloxx Pharmaceuticals. Eloxx Pharmaceuticals, Inc. Eloxx Pharmaceuticals, Inc. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. SOURCE: Eloxx Pharmaceuticals, Inc. WALTHAM, Mass., Source link.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

The Pharma Data

OCTOBER 20, 2020

21, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. About Ionis Pharmaceuticals As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.

RNA 52

RNA Pharmaceuticals Disease Treatment 52

Broad Institute

NOVEMBER 7, 2023

To “deconstruct” RA pathology on a cellular level, the researchers combined surface protein data and histologic analysis with multiple forms of single-cell RNA-sequencing and bulk RNA sequencing. Paper cited Zhang F, et al.

Treatment 96

Treatment RNA Hospitals Disease 96

Dark Matter Blog

JANUARY 16, 2023

We are moving rapidly toward escape velocity in our RNA expedition at Arrakis. For those of you joining us for the first time, it’s worth a quick look back at why we decided to go all-in on the RNA world, why people thought we were crazy, and why we know we’re not. Our terra firma is small-molecule medicines.

Small Molecule 52

Small Molecule RNA Drugs Disease 52

The Pharma Data

DECEMBER 2, 2020

She is currently the CEO of Twentyeight-Seven, a biotech company focused on novel RNA biology that she co-founded alongside prominent Harvard investigators. Lisa is a senior pharmaceutical executive with more than 20 years of experience in research and drug discovery. 3, 2020 08:00 UTC.

Pharmaceuticals 52

Pharmaceuticals Synthetic Chemistry RNA Disease 52

Dark Matter Blog

JULY 16, 2021

As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I wanted to use molecular biology to create drugs.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

PerkinElmer

JULY 13, 2020

Imaging Modalities Help Visualize and Confirm Findings An emerging method of studying viruses is by using high-content imaging solutions to visualize the activity of small interfering RNA (siRNA), also known as short interfering RNA or “silencing” RNA.

RNA 52

RNA Virus Laboratories Science 52

The Pharma Data

DECEMBER 8, 2020

The fully integrated pharmaceutical company creates value through China’s specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory. SciNeuro Pharmaceuticals . Laying down a new track for RNA processing, Remix launched with $81 million in financing. Nuance Pharma .

RNA 52

RNA Therapies Disease Protein Expression 52

Drug Target Review

APRIL 9, 2024

In a previous study, we showed that these peptides decorate all cellular RNAs and thus impair the binding of RNA-binding proteins to RNA. These compounds were later licensed to the pharmaceutical industry for clinical development. However, the mechanism of this observation was not fully understood.

RNA 64

RNA Cell Biology Clinical Development DNA 64

DrugBank

MAY 15, 2024

Another promising avenue is the use of technologies like RNA interference and gene editing, which allow scientists to turn off the production of certain proteins altogether. These methods could bypass the need to directly target these proteins with traditional drugs.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98

New Drug Approvals

SEPTEMBER 6, 2024

TLR7-9 are among the set that are endosomally located and respond to single-stranded RNA (TLR7and TLR8) or unmethylated single-stranded DNA containing cytosine-phosphate-guanine (CpG) motifs (TLR9). A total of 13 TLR family members have been identified, 10 in human, that span either the cell surface or the endosomal compartment.

RNA 62

RNA Clinical Trials DNA Disease 62

The Open Targets Blog

MAY 23, 2024

In a paper published today in Nature Communications , Open Targets researchers and collaborators used single-cell RNA sequencing to create a high resolution molecular map of immune cells in NSCLC tumours, to better understand the role of these cells in disease progression. This could then pave the way for subtype-specific therapies.

RNA 57

RNA Disease Clinical Trials Therapies 57

The Pharma Data

DECEMBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. Galidesivir treatment was associated with a more rapid decline in viral RNA levels in the respiratory tract in an apparent dose-dependent manner. RESEARCH TRIANGLE PARK, N.C., It is in advanced development for the treatment of Marburg virus disease.

Clinical Trials 52

Clinical Trials Virus RNA Trials 52

Drug Target Review

JULY 11, 2024

Ribonucleic acid (RNA) sequencing is an established approach, in which messenger RNA (mRNA) transcripts within the cell are used to produce a readout of the proteins they code for on the cell surface. However, this approach may unlock valuable new insights that could ultimately save or prolong patients’ lives. in 2019.

Therapies 56

Therapies RNA Pharma Companies Disease 56

The Pharma Data

DECEMBER 8, 2020

8, 2020 /PRNewswire/ — At its Investor Day yesterday, Ionis Pharmaceuticals, Inc. About Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals is a trademark of Ionis Pharmaceuticals, Inc. SOURCE Ionis Pharmaceuticals, Inc. . Potential to launch 6+ new products in next five years. Monia , Ph.D.,

RNA 52

RNA Pharmaceuticals Disease Treatment 52

The Pharma Data

NOVEMBER 29, 2020

Vanda Pharmaceuticals’ Hetlioz for Smith-Magenis Syndrome. Vanda Pharmaceuticals has a target action date of December 1 for the capsules and liquid formulation of Hetlioz for adults and children—the capsule formulation is a supplemental NDA (sNDA) and the liquid formulation is an NDA. It is an RNA interference (RNAi) therapeutic.

FDA 52

FDA Licensing Licensing Pharmaceuticals 52

The Pharma Data

MARCH 28, 2022

Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. We designed BIIB078 to test the prevailing hypothesis that the mechanisms of disease for C9orf72-associated ALS were caused by toxicity associated with the repeat containing RNA and corresponding dipeptides. About Ionis Pharmaceuticals, Inc. Biogen Inc.

RNA 52

RNA Therapies Disease Biosimilars 52

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. For more information, please visit www.BioNTech.de.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

Drug Target Review

AUGUST 16, 2024

I joined the pharmaceutical industry to leverage my passion and hands-on clinical experience to care for people all over the world by bringing a unique perspective to drug and device research and development.

Medical Schools 111

Medical Schools Nurses Research Production 111

Elrig

APRIL 29, 2024

She has played a key role inbuilding the target identification platform and a proprietary database of transcriptome-wide, functional RNA structures. With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

The Pharma Data

DECEMBER 17, 2020

Since announcing the Early Access Program on December 8, response from top academic institutions and leading pharmaceutical companies around the world has exceeded our expectations,” said Byron Lawson, Chief Commercial Officer.

Laboratories 52

Laboratories Pharmaceutical Companies Production RNA 52

The Pharma Data

NOVEMBER 22, 2020

Back in September, Vertex Pharmaceuticals and CRISPR Therapeutics – the company behind the CRISPR Cas-9 platform – announced that the European Medicines Agency (EMA) had granted Priority Medicines (PRIME) designation to CTX001, an investigational ex vivo CRISPR Cas-9 gene-edited therapy for the treatment of severe sickle cell disease. .

DNA 52

DNA Medical Schools Treatment RNA 52

The Pharma Data

AUGUST 31, 2020

About the cobas HIV-1/HIV-2 Qualitative Test cobas HIV-1/HIV-2 Qualitative for use on the cobas 6800/8800 Systems is an in vitro nucleic acid amplification test for the qualitative detection and differentiation of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) RNA in human serum and plasma. .

FDA Approval 52

FDA Approval FDA Virus Disease 52

The Pharma Data

SEPTEMBER 30, 2021

” To solve those problems, Varadarajan collaborated with Xinli Liu, professor of pharmaceutics at the UH College of Pharmacy, and an expert in nanoparticle delivery. Liu’s team was ready to encapsulate the agonist of the stimulator of interferon genes (STING) within liposomal particles to yield the adjuvant named NanoSTING. .

Vaccine 52

Vaccine Disease Immune Response Virus 52

Sygnature Discovery

JUNE 17, 2024

Biophysics in Drug Discovery: A Sygnature Approach Our key biophysics leaders alone possess over 50 years of combined experience in drug discovery, spanning CRO, pharmaceutical, and biotech sectors, and applied across various target classes and therapeutic modalities. Nucleic Acid Targets: Focusing on specific interactions and functions.

Biophysical Assays 52

Biophysical Assays Screening Hits Assay Development Fragment Screening 52

The Pharma Data

OCTOBER 28, 2021

1), (2), (3) Interim findings were presented at the 18th European AIDS Conference (EACS 2021) being held 27-30 October. Utmost people living with HIV on the trial agreed or fully agreed that long- acting cabotegravir and rilpivirine was largely respectable, applicable and doable to apply ( mean scores of4.6,4.6,4.6

Pharmaceutical Companies 52

Pharmaceutical Companies Treatment RNA Pharmaceuticals 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic. Download this exclusive report here. Source link.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

JULY 6, 2021

Fitusiran is an investigational, subcutaneously administered small interference RNA therapy in development for the treatment of people with hemophilia A or B, with or without inhibitors and has the potential to transform treatment as it would be the only prophylactic therapy with as few as six injections per year.

Therapies 52

Therapies Pharmacokinetics Treatment RNA 52

The Pharma Data

DECEMBER 13, 2020

Prior to that, he held various oncology research and development positions at Merrimack Pharmaceuticals and Archemix. Before that, he was Director of Development at Cobalt Biomedicine leading CAR-T and other cell/gene therapy programs, and R&D Director at OvaScience developing stem cell-based products. He received his B.S.

Medical Schools 40

Medical Schools Clinical Development Therapies RNA 40

The Pharma Data

NOVEMBER 16, 2020

We believe that our investments in mRNA delivery technology and manufacturing process development will allow us to store and ship our COVID-19 vaccine candidate at temperatures commonly found in readily available pharmaceutical freezers and refrigerators,” said Juan Andres, Chief Technical Operations and Quality Officer at Moderna. “We

Vaccine 52

Vaccine FDA Clinical Trials Pharmacy 52

The Pharma Data

OCTOBER 28, 2020

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co., .–( BUSINESS WIRE )– Moderna, Inc.

Vaccine 40

Vaccine Government Clinical Trials RNA 40

New Drug Approvals

SEPTEMBER 7, 2024

Coronaviruses are enveloped, positive-sense, single-stranded RNA viruses. The genomic RNA of CoVs has a 5′-cap structure and 3′-poly-A tail and contains at least 6 open reading frames (ORFs). WO/2022/109363 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS Enanta Pharmaceuticals, Inc. Patent CN114524821A.

RNA 62

RNA Virus Therapies Pharmaceuticals 62

The Pharma Data

MARCH 5, 2021

This will be adapted to the needs of messenger RNA vaccine production for CureVac’s CVnCoV, the manufacturing of which is highly complex. At the Kundl site, Novartis is a pioneer and has decades of experience in pharmaceutical production of proteins and in more recent years of nucleic acids.

Vaccine 52

Vaccine Production Biosimilars Hospitals 52

The Pharma Data

JANUARY 17, 2021

The treatments all use the antisense technology and automation techniques developed at Ionis Pharmaceuticals , which Crooke founded. That’s not the case with RNA-targeted drugs. “It’s the cause of the mutation, not the name of the disease, that matters.”.

Disease 52

Disease Clinical Trials Small Molecule Treatment 52

The Pharma Data

SEPTEMBER 1, 2020

In general, antigen tests have a high specificity, though are not as sensitive as molecular tests that amplify the target viral DNA or RNA sequence in order to generate a quantifiable signal to indicate the presence of the virus in a sample. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Virus 52

Virus Laboratories Clinical Trials Treatment 52

The Pharma Data

NOVEMBER 16, 2020

It combines Moderna’s mRNA (messenger RNA) delivery platform with the stabilized SARS-CoV-2 spike immunogen (S-2P) developed by NIAID scientists. The mRNA-1273 vaccine candidate was co-developed by the Cambridge, Massachusetts-based biotechnology company Moderna, Inc.,

Clinical Trials 52

Clinical Trials Vaccine Trials FDA Approval 52